CL2014001131A1 - Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar un trastorno de proliferacion celular, tal como cancer de mama, colorrectal, de piel, del snc y de higado. - Google Patents

Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar un trastorno de proliferacion celular, tal como cancer de mama, colorrectal, de piel, del snc y de higado.

Info

Publication number: CL2014001131A1
Authority: CL; Chile
Prior art keywords: snc; pyrido; colorectal; pyrimidine; breast
Prior art date: 2011-11-04

Application number

CL2014001131A

Other languages

English (en)

Inventor

David Campell

Sergio G Duron

Original Assignee

Afraxis Holdings Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-04

Filing date

2014-04-30

Publication date

2014-08-22

2014-04-30 Application filed by Afraxis Holdings Inc filed Critical Afraxis Holdings Inc

2014-08-22 Publication of CL2014001131A1 publication Critical patent/CL2014001131A1/es

Links

WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 title 1
125000003118 aryl group Chemical group 0.000 title 1
210000000481 breast Anatomy 0.000 title 1
208000035269 cancer or benign tumor Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
201000007270 liver cancer Diseases 0.000 title 1
208000014018 liver neoplasm Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CL2014001131A 2011-11-04 2014-04-30 Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar un trastorno de proliferacion celular, tal como cancer de mama, colorrectal, de piel, del snc y de higado. CL2014001131A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161555902P	2011-11-04	2011-11-04

Publications (1)

Publication Number	Publication Date
CL2014001131A1 true CL2014001131A1 (es)	2014-08-22

Family

ID=48192852

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2014001132A CL2014001132A1 (es)	2011-11-04	2014-04-30	Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar el sindrome del x fragil.
CL2014001131A CL2014001131A1 (es)	2011-11-04	2014-04-30	Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar un trastorno de proliferacion celular, tal como cancer de mama, colorrectal, de piel, del snc y de higado.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2014001132A CL2014001132A1 (es)	2011-11-04	2014-04-30	Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar el sindrome del x fragil.

Country Status (20)

Country	Link
US (2)	US20150031693A1 (es)
EP (2)	EP2773642A1 (es)
JP (2)	JP2015501786A (es)
KR (2)	KR20140096098A (es)
CN (2)	CN104039786A (es)
AR (1)	AR089175A1 (es)
AU (2)	AU2012327183A1 (es)
BR (2)	BR112014010631A2 (es)
CA (2)	CA2854462A1 (es)
CL (2)	CL2014001132A1 (es)
CO (1)	CO7030960A2 (es)
CR (2)	CR20140250A (es)
EA (2)	EA201490927A1 (es)
IL (2)	IL232154A0 (es)
MA (2)	MA35660B1 (es)
MX (2)	MX2014005296A (es)
PH (2)	PH12014500956A1 (es)
SG (2)	SG11201401996TA (es)
TW (1)	TW201326169A (es)
WO (2)	WO2013067434A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011156780A2 (en) *	2010-06-10	2011-12-15	Afraxis, Inc.	8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
SG11201401937YA (en)	2011-11-04	2014-05-29	Hoffmann La Roche	New aryl-quinoline derivatives
TWI647220B (zh)	2013-03-15	2019-01-11	美商西建卡爾有限責任公司	雜芳基化合物及其用途
MY181020A (en)	2013-03-15	2020-12-16	Sanofi Sa	Heteroaryl compounds and uses thereof
WO2015011252A1 (en) *	2013-07-26	2015-01-29	F. Hoffmann-La Roche Ag	Pyrimidine-pyridinone serine/threonine kinase inhibitors
DK3102577T3 (en) *	2014-02-07	2018-11-12	Principia Biopharma Inc	QUINOLONDERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
MA38393B1 (fr)	2014-03-13	2018-11-30	Sanofi Sa	Composés hétéroaryle et utilisations associées
WO2016015597A1 (en)	2014-07-26	2016-02-04	Sunshine Lake Pharma Co., Ltd.	Compounds as cdk small-molecule inhibitors and uses thereof
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
CA3013959C (en) *	2016-02-17	2024-05-28	Nuralogix Corporation	System and method for detecting physiological state
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
JP7090037B2 (ja) *	2016-06-23	2022-06-23	エフ．ホフマン－ラロシュアーゲー	新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
US11685954B2 (en) *	2016-07-15	2023-06-27	Dana-Farber Cancer Institute, Inc.	Biomarkers predictive of endocrine resistance in breast cancer
CN106818805A (zh) *	2016-12-27	2017-06-13	东莞市联洲知识产权运营管理有限公司	一种天然乙酰胆碱酯酶抑制剂及其杀虫应用
CN107083428B (zh) *	2017-04-10	2020-09-25	徐州医科大学	Pak5在癌症诊断预后治疗及药物筛选中的应用
TWI831829B (zh)	2018-09-12	2024-02-11	美商建南德克公司	苯氧基-吡啶基-嘧啶化合物及使用方法
US20220002429A1 (en) *	2018-10-24	2022-01-06	Northwestern University	Tumor cell aggregation inhibitors' for treating cancer
WO2020142612A1 (en) *	2019-01-03	2020-07-09	Genentech, Inc.	Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
CN112213400B (zh) *	2019-07-09	2022-06-07	四川弘合生物科技有限公司	一种β-榄香烯及其有关物质的检测方法
CN110496128B (zh) *	2019-09-23	2022-09-30	吉林大学	利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
PE20231311A1 (es)	2020-11-18	2023-08-24	Deciphera Pharmaceuticals Llc	Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
CN117858879A (zh) *	2021-01-15	2024-04-09	南京再明医药有限公司	Cdk2/4/6抑制剂及其制备方法和应用
CN113046323A (zh) *	2021-04-02	2021-06-29	四川农业大学	一种基于miR-532-5p及其靶基因调控卵巢颗粒细胞的方法
MX2024006627A (es)	2021-12-03	2024-08-22	Deciphera Pharmaceuticals Llc	Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
WO2025257301A1 (en) *	2024-06-13	2025-12-18	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Treatment of neurofibromatosis type 2 by inhibitors of g6pd, acsl3 and/or oxsm

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1201765A3 (en) *	2000-10-16	2003-08-27	Axxima Pharmaceuticals Aktiengesellschaft	Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2008055842A1 (en) *	2006-11-09	2008-05-15	F. Hoffmann-La Roche Ag	Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
EP2112150B1 (en) *	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
WO2010071846A2 (en) *	2008-12-19	2010-06-24	Afraxis, Inc.	Compounds for treating neuropsychiatric conditions
CN102648200A (zh) *	2009-10-09	2012-08-22	亚弗克希斯公司	用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
EP2580214A4 (en) *	2010-06-09	2013-12-04	Afraxis Holdings Inc	8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011156780A2 (en) *	2010-06-10	2011-12-15	Afraxis, Inc.	8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

2012
- 2012-11-02 BR BR112014010631A patent/BR112014010631A2/pt not_active Application Discontinuation
- 2012-11-02 SG SG11201401996TA patent/SG11201401996TA/en unknown
- 2012-11-02 US US14/356,118 patent/US20150031693A1/en not_active Abandoned
- 2012-11-02 BR BR112014010420A patent/BR112014010420A2/pt not_active Application Discontinuation
- 2012-11-02 CN CN201280066130.4A patent/CN104039786A/zh active Pending
- 2012-11-02 JP JP2014540157A patent/JP2015501786A/ja active Pending
- 2012-11-02 JP JP2014540152A patent/JP2014532724A/ja active Pending
- 2012-11-02 CA CA2854462A patent/CA2854462A1/en not_active Abandoned
- 2012-11-02 AU AU2012327183A patent/AU2012327183A1/en not_active Abandoned
- 2012-11-02 PH PH1/2014/500956A patent/PH12014500956A1/en unknown
- 2012-11-02 WO PCT/US2012/063426 patent/WO2013067434A1/en not_active Ceased
- 2012-11-02 KR KR1020147014683A patent/KR20140096098A/ko not_active Withdrawn
- 2012-11-02 MX MX2014005296A patent/MX2014005296A/es not_active Application Discontinuation
- 2012-11-02 KR KR1020147014685A patent/KR20140105451A/ko not_active Withdrawn
- 2012-11-02 US US13/668,079 patent/US20130116263A1/en not_active Abandoned
- 2012-11-02 CA CA2854471A patent/CA2854471A1/en not_active Abandoned
- 2012-11-02 CN CN201280066127.2A patent/CN104093717A/zh active Pending
- 2012-11-02 AU AU2012327187A patent/AU2012327187A1/en not_active Abandoned
- 2012-11-02 EP EP12844804.0A patent/EP2773642A1/en not_active Ceased
- 2012-11-02 MX MX2014005292A patent/MX2014005292A/es not_active Application Discontinuation
- 2012-11-02 WO PCT/US2012/063413 patent/WO2013067423A1/en not_active Ceased
- 2012-11-02 EA EA201490927A patent/EA201490927A1/ru unknown
- 2012-11-02 EP EP12845870.0A patent/EP2773643A4/en not_active Withdrawn
- 2012-11-02 EA EA201490925A patent/EA201490925A1/ru unknown
- 2012-11-02 SG SG11201401914WA patent/SG11201401914WA/en unknown
- 2012-11-05 TW TW101141080A patent/TW201326169A/zh unknown
- 2012-11-05 AR ARP120104155A patent/AR089175A1/es unknown
2014
- 2014-04-22 IL IL232154A patent/IL232154A0/en unknown
- 2014-04-24 IL IL232215A patent/IL232215A0/en unknown
- 2014-04-30 CL CL2014001132A patent/CL2014001132A1/es unknown
- 2014-04-30 CL CL2014001131A patent/CL2014001131A1/es unknown
- 2014-05-02 PH PH12014500995A patent/PH12014500995A1/en unknown
- 2014-05-26 CR CR20140250A patent/CR20140250A/es unknown
- 2014-05-26 MA MA37064A patent/MA35660B1/fr unknown
- 2014-05-26 MA MA37065A patent/MA35661B1/fr unknown
- 2014-05-26 CR CR20140251A patent/CR20140251A/es unknown
- 2014-06-04 CO CO14119704A patent/CO7030960A2/es unknown

Also Published As

Publication number	Publication date
EP2773642A1 (en)	2014-09-10
IL232215A0 (en)	2014-06-30
TW201326169A (zh)	2013-07-01
MX2014005296A (es)	2014-08-27
EA201490925A1 (ru)	2014-09-30
WO2013067434A1 (en)	2013-05-10
US20130116263A1 (en)	2013-05-09
US20150031693A1 (en)	2015-01-29
BR112014010420A2 (pt)	2017-04-25
SG11201401914WA (en)	2014-05-29
AU2012327183A8 (en)	2013-07-18
CA2854471A1 (en)	2013-05-10
BR112014010631A2 (pt)	2017-04-25
EA201490927A1 (ru)	2014-10-30
CA2854462A1 (en)	2013-05-10
MX2014005292A (es)	2014-09-11
MA35660B1 (fr)	2014-11-01
CO7030960A2 (es)	2014-08-21
CN104093717A (zh)	2014-10-08
CR20140250A (es)	2014-08-20
EP2773643A4 (en)	2015-07-29
MA35661B1 (fr)	2014-11-01
PH12014500995A1 (en)	2014-08-04
AU2012327183A1 (en)	2013-05-30
IL232154A0 (en)	2014-05-28
KR20140096098A (ko)	2014-08-04
CN104039786A (zh)	2014-09-10
SG11201401996TA (en)	2014-05-29
JP2014532724A (ja)	2014-12-08
WO2013067423A1 (en)	2013-05-10
AU2012327187A8 (en)	2013-07-25
PH12014500956A1 (en)	2014-06-30
CL2014001132A1 (es)	2014-08-22
JP2015501786A (ja)	2015-01-19
EP2773643A1 (en)	2014-09-10
CR20140251A (es)	2014-08-20
AR089175A1 (es)	2014-08-06
KR20140105451A (ko)	2014-09-01
AU2012327187A1 (en)	2013-05-23

Publication	Publication Date	Title
CL2014001132A1 (es)	2014-08-22	Compuestos derivados de 6-(aril)pirido[2,3-d]pirimidina-7(8h)-ona, o una sal o n-oxido de los mismos, como inhibidores de pak; composicion farmaceutica que los comprende, util para tratar el sindrome del x fragil.
IL274647A (en)	2020-06-30	Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
CL2014003355A1 (es)	2015-06-12	Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
PL2922828T3 (pl)	2020-12-28	Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
PL3074396T3 (pl)	2019-11-29	Pochodne 1-(5-tert-butylo-2-arylopirazol-3-ilo)-3-[2-fluoro-4-[(3-okso-4h-pirydo[2,3-b]pirazyn-8-ylo)oksy]fenylo]mocznika jako inhibitory RAF do leczenia nowotworu
LT2807159T (lt)	2017-01-10	Nauji indolizino junginiai, jų gamybos būdai ir juos turinčios farmacinės kompozicijos, skirtos vėžio gydymui
EA201491456A1 (ru)	2014-12-30	Соединения-ингибиторы raf
CL2013000935A1 (es)	2013-07-05	Compuestos derivados de bencimidazol o sus sales, como inhibidores de cinasa pi3; composicion farmaceutica que los comprende; y su uso para el tratamiento de un neoplasma deficiente en pten seleccionado entre gliomas de cerebro, cancer de mama, cancer de prostata, cancer gastrico y mieloma multiple, entre otros.
PT3456717T (pt)	2021-05-26	Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
IL258231A (en)	2018-05-31	New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
IL242881B (en)	2019-09-26	A toxic substance for use in combination with radiation in cancer treatment
MX2013011518A (es)	2014-06-04	8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
HUE037645T2 (hu)	2018-09-28	Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok
EP2968375A4 (en)	2016-08-03	PROCESS FOR THE PREPARATION OF SGLT2 INHIBITORS
PT3597649T (pt)	2022-01-21	Composições contendo compostos substituidos de [1,2,4]triazolo[1,5-a] pirimidin-7il como inibidores de pde2
IL238662A (en)	2017-08-31	Bandostatin derivatives, containing them and used to treat cancer
SG11201506980PA (en)	2015-10-29	Forward osmosis system using coordination complexes
EP3207377A4 (en)	2018-05-02	Circulating tumor cell diagnostics for therapy targeting pd-l1
MX367387B (es)	2019-08-19	Activadores de cinasa de piruvato para su uso en terapia.
PL2729008T3 (pl)	2017-10-31	Systemy, sposoby i formulacje do leczenia raka
IL258341A (en)	2018-05-31	New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
IL262656A (en)	2018-12-31	Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
NZ726050A (en)	2018-04-27	Modulators of androgen synthesis
IL237976A0 (en)	2015-05-31	A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors
EP3020399A4 (en)	2016-12-28	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER